ResearcherHospital Israelita Albert EinsteinActive in the last 2 years
Fernando Moura
Matched on ORCID iD 0000-0003-1967-1544; OpenAlex author ID A5103818279, A5110956423. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 0, last author 3)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 10
2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: none · 2026: 1 paper
Papers 5
- Efficacy and safety signals from early-phase studies of KRAS inhibition in pancreatic cancer. Co-author DOI 10.1038/s41598-026-40757-3↗
- Concomitant or antecedent intraductal papillary mucinous neoplasm is not a prognostic factor in resected pancreatic cancer. Last author DOI 10.21037/jgo-24-157↗
- Does neoadjuvant treatment in resectable pancreatic cancer improve overall survival? A systematic review and meta-analysis of randomized controlled trials. Last author DOI 10.1016/j.esmoop.2022.100771↗
- Neoadjuvant chemotherapy or upfront surgery in localized pancreatic cancer: a contemporary analysis. Last author DOI 10.1038/s41598-022-17743-6↗
- Predictive Value of Serum Carbohydrate Antigen 19-9 (CA19-9) for Early Mortality in Advanced Pancreatic Cancer. Co-author DOI 10.1007/s12029-017-0007-x↗
Closest collaborators
The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Pedro Luiz Serrano Usón · 5 shared papers, 2018–2026 · strength 0.93
- Paper Efficacy and safety signals from early-phase studies of KRAS inhibition in pancreatic cancer. DOI 10.1038/s41598-026-40757-3↗
- Paper Does neoadjuvant treatment in resectable pancreatic cancer improve overall survival? A systematic review and meta-analy… DOI 10.1016/j.esmoop.2022.100771↗
- Paper Concomitant or antecedent intraductal papillary mucinous neoplasm is not a prognostic factor in resected pancreatic can… DOI 10.21037/jgo-24-157↗
- Mitesh J. Borad · 3 shared papers, 2023–2026 · strength 0.68
- Paper Efficacy and safety signals from early-phase studies of KRAS inhibition in pancreatic cancer. DOI 10.1038/s41598-026-40757-3↗
- Paper Does neoadjuvant treatment in resectable pancreatic cancer improve overall survival? A systematic review and meta-analy… DOI 10.1016/j.esmoop.2022.100771↗
- Paper Concomitant or antecedent intraductal papillary mucinous neoplasm is not a prognostic factor in resected pancreatic can… DOI 10.21037/jgo-24-157↗
- Kathlen Oliveira Martins Tiede · 1 shared paper, 2026 · strength 0.30
- Mohamad Bassam Sonbol · 1 shared paper, 2026 · strength 0.30
- Tanios Bekaii‐Saab · 1 shared paper, 2026 · strength 0.30
- Diogo Diniz Gomes Bugano · 2 shared papers, 2018–2024 · strength 0.30
- Paper Concomitant or antecedent intraductal papillary mucinous neoplasm is not a prognostic factor in resected pancreatic can… DOI 10.21037/jgo-24-157↗
- Paper Predictive Value of Serum Carbohydrate Antigen 19-9 (CA19-9) for Early Mortality in Advanced Pancreatic Cancer. DOI 10.1007/s12029-017-0007-x↗
- Douglas Dias e Silva · 1 shared paper, 2023 · strength 0.19
- Francisco Tustumi · 1 shared paper, 2024 · strength 0.18
- Guilherme Naccache Namur · 1 shared paper, 2024 · strength 0.18
- Gehan Botrus · 1 shared paper, 2022 · strength 0.14
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.